K.L. Choy

Keilung Choy, Wei Xie, Keqi Wang

Bioprocess mechanistic modeling is essential for advancing intelligent digital twin representation of biomanufacturing, yet challenges persist due to complex intracellular regulation, stochastic system behavior, and limited experimental data. This paper introduces a symbolic and statistical learning framework to identify key regulatory mechanisms and quantify model uncertainty. Bioprocess dynamics is formulated with stochastic differential equations characterizing intrinsic process variability, with a predefined set of candidate regulatory mechanisms constructed from biological knowledge. A Bayesian learning approach is developed, which is based on a joint learning of kinetic parameters and regulatory structure through a formulation of the mixture model. To enhance computational efficiency, a Metropolis-adjusted Langevin algorithm with adjoint sensitivity analysis is developed for posterior exploration. Compared to state-of-the-art Bayesian inference approaches, the proposed framework achieves improved sample efficiency and robust model selection. An empirical study demonstrates its ability to recover missing regulatory mechanisms and improve model fidelity under data-limited conditions.

Hua Zheng, Wei Xie, Ilya O. Ryzhov et al.

This paper presents a novel methodological framework, called the Actor-Simulator, that incorporates the calibration of digital twins into model-based reinforcement learning for more effective control of stochastic systems with complex nonlinear dynamics. Traditional model-based control often relies on restrictive structural assumptions (such as linear state transitions) and fails to account for parameter uncertainty in the model. These issues become particularly critical in industries such as biopharmaceutical manufacturing, where process dynamics are complex and not fully known, and only a limited amount of data is available. Our approach jointly calibrates the digital twin and searches for an optimal control policy, thus accounting for and reducing model error. We balance exploration and exploitation by using policy performance as a guide for data collection. This dual-component approach provably converges to the optimal policy, and outperforms existing methods in extensive numerical experiments based on the biopharmaceutical manufacturing domain.